Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-12-05

Clinical Trial Update: Ripretinib (QINLOCK®) According to Current SmPC

View source ↗

Summary

Ripretinib for Gastrointestinal stromal tumor has a completed trial (NCT06619275). The update indicates that the trial findings are consistent with the current …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • QINLOCK (ripretinib)

Snippet

Sponsor: iOMEDICO AG | Conditions: GIST - Gastrointestinal Stromal Tumor | Status: COMPLETED